| 2.61 0.07 (2.76%) | 06-29 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.15 | 1-year : | 3.36 |
| Resists | First : | 2.7 | Second : | 2.88 |
| Pivot price | 2.56 |
|||
| Supports | First : | 2.42 | Second : | 2.01 |
| MAs | MA(5) : | 2.57 |
MA(20) : | 2.59  |
| MA(100) : | 2.33 |
MA(250) : | 2.41 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 50.5 |
D(3) : | 47.5 |
| RSI | RSI(14): 52.4 |
|||
| 52-week | High : | 3.28 | Low : | 1.76 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ KPRX ] has closed below upper band by 27.4%. Bollinger Bands are 54% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.64 - 2.66 | 2.66 - 2.67 |
| Low: | 2.52 - 2.54 | 2.54 - 2.55 |
| Close: | 2.58 - 2.61 | 2.61 - 2.64 |
Kiora Pharmaceuticals, Inc., a specialty pharmaceutical firm operating at the clinical stage, is dedicated to the creation and commercialization of treatments for various ophthalmic conditions across the United States. Its flagship therapeutic candidate, KIO-301, is a groundbreaking small molecule undergoing Phase 1 clinical trials. This innovative "photoswitch" aims to revitalize vision in individuals suffering from both inherited and age-related forms of retinal degeneration. The company's pipeline also includes KIO-101, an eye drop currently in Phase 2 trials for addressing the ocular manifestations of rheumatoid arthritis, as well as non-infectious posterior uveitis. Furthermore, Kiora is advancing KIO-201, another eye drop, which is in Phase 3 clinical trials, designed to facilitate corneal wound healing following PRK surgery. Established in 1998, the company adopted its current name in November 2021, having previously operated as Eyegate Pharmaceuticals, Inc. Kiora Pharmaceuticals maintains its corporate headquarters in Salt Lake City, Utah.
Fri, 26 Jun 2026
KPRX Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 19 Jun 2026
KPRX SEC Filings - KIORA PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 18 Jun 2026
Kiora Pharmaceuticals Inc (KPRX) Institutional Confidence - TradingKey
Wed, 17 Jun 2026
Kiora Pharmaceuticals Inc (KPRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Fri, 12 Jun 2026
Director at Kiora (KPRX) receives 25,000 stock options at $2.63 strike - Stock Titan
Fri, 12 Jun 2026
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 3 (%) |
| Held by Institutions | 28.7 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 22 (K) |
| EPS | -2.71 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.49 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.5 % |
| Return on Equity (ttm) | -58.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.92 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.23 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.97 |
| PEG Ratio | 0 |
| Price to Book value | 0.74 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|